» Articles » PMID: 32019907

Chondroitin Sulfate Synthase 1 Enhances Proliferation of Glioblastoma by Modulating PDGFRA Stability

Overview
Journal Oncogenesis
Date 2020 Feb 6
PMID 32019907
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Chondroitin sulfate synthases, a family of enzyme involved in chondroitin sulfate (CS) polymerization, are dysregulated in various human malignancies, but their roles in glioma remain unclear. We performed database analysis and immunohistochemistry on human glioma tissue, to demonstrate that the expression of CHSY1 was frequently upregulated in glioma, and that it was associated with adverse clinicopathologic features, including high tumor grade and poor survival. Using a chondroitin sulfate-specific antibody, we showed that the expression of CHSY1 was significantly associated with CS formation in glioma tissue and cells. In addition, overexpression of CHSY1 in glioma cells enhanced cell viability and orthotopic tumor growth, whereas CHSY1 silencing suppressed malignant growth. Mechanistic investigations revealed that CHSY1 selectively regulates PDGFRA activation and PDGF-induced signaling in glioma cells by stabilizing PDGFRA protein levels. Inhibiting PDGFR activity with crenolanib decreased CHSY1-induced malignant characteristics of GL261 cells and prolonged survival in an orthotopic mouse model of glioma, which underlines the critical role of PDGFRA in mediating the effects of CHSY1. Taken together, these results provide information on CHSY1 expression and its role in glioma progression, and highlight novel insights into the significance of CHSY1 in PDGFRA signaling. Thus, our findings point to new molecular targets for glioma treatment.

Citing Articles

Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment.

Zheng Y, Xu R, Chen X, Lu Y, Zheng J, Lin Y Cell Death Dis. 2024; 15(10):775.

PMID: 39461979 PMC: 11513100. DOI: 10.1038/s41419-024-07122-6.


The prognostic implications and tumor-promoting functions of CHSY3 in gastric cancer.

Wang H, Zhang J, Wei Z, Chen S, Zheng J, Li Y Front Immunol. 2024; 15:1364979.

PMID: 38812506 PMC: 11133601. DOI: 10.3389/fimmu.2024.1364979.


CHST11-modified chondroitin 4-sulfate as a potential therapeutic target for glioblastoma.

Lin Y, Chu Y, Liao W, Chen C, Hsiao W, Ho Y Am J Cancer Res. 2023; 13(7):2998-3012.

PMID: 37559985 PMC: 10408464.


Targeting Chondroitin Sulphate Synthase 1 (Chsy1) Promotes Axon Growth Following Neurorrhaphy by Suppressing Versican Accumulation.

Liu C, Ho Y, Wang C, Hsu C, Chu Y, Hsu M Molecules. 2023; 28(9).

PMID: 37175152 PMC: 10180239. DOI: 10.3390/molecules28093742.


Glioblastoma: Current Status, Emerging Targets, and Recent Advances.

Thakur A, Faujdar C, Sharma R, Sharma S, Malik B, Nepali K J Med Chem. 2022; 65(13):8596-8685.

PMID: 35786935 PMC: 9297300. DOI: 10.1021/acs.jmedchem.1c01946.


References
1.
Munkley J, Elliott D . Hallmarks of glycosylation in cancer. Oncotarget. 2016; 7(23):35478-89. PMC: 5085245. DOI: 10.18632/oncotarget.8155. View

2.
Djerbal L, Lortat-Jacob H, Kwok J . Chondroitin sulfates and their binding molecules in the central nervous system. Glycoconj J. 2017; 34(3):363-376. PMC: 5487772. DOI: 10.1007/s10719-017-9761-z. View

3.
Kwok J, Warren P, Fawcett J . Chondroitin sulfate: a key molecule in the brain matrix. Int J Biochem Cell Biol. 2012; 44(4):582-6. DOI: 10.1016/j.biocel.2012.01.004. View

4.
Keough M, Rogers J, Zhang P, Jensen S, Stephenson E, Chen T . An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination. Nat Commun. 2016; 7:11312. PMC: 4853428. DOI: 10.1038/ncomms11312. View

5.
Bradbury E, Moon L, Popat R, King V, Bennett G, Patel P . Chondroitinase ABC promotes functional recovery after spinal cord injury. Nature. 2002; 416(6881):636-40. DOI: 10.1038/416636a. View